ReviewReumatologia2026
Risk of venous, arterial, and rare thrombotic events in adults with Sjögren's disease: a systematic review and meta-analysis.
Review in Reumatologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sjögren's disease (SjD) is associated with increased thrombotic and cardiovascular risk. We systematically reviewed and meta-analyzed venous, arterial, and rare vascular outcomes in SjD. Following PRISMA 2020 (PROSPERO registered), we searched major databases without language restrictions, extracted adjusted estimates, and graded certainty using GRADE. Twelve studies (> 426,000 participants) met the criteria. Venous thromboembolism (VTE) showed a consistent, clinically important increase (≈ twofold). Arterial outcomes - ischemic stroke, myocardial infarction, and composite major adverse cardiovascular events - were heterogeneous, varying by age and geographic region. Heart failure, predominantly with preserved ejection fraction, was increased across settings. Rare events (e.g., cerebral venous thrombosis, thrombotic microangiopathy) were described narratively. Sjögren's disease is associated with substantially increased venous thrombotic risk, variable arterial associations, and an under-recognized burden of heart failure. Clinical care should combine risk-stratified VTE prevention with rigorous cardiovascular risk management. Research priorities include harmonized, multi-ethnic cohorts and prospective trials testing time-limited thromboprophylaxis during high-risk windows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.